CD19 and acute lymphoblastic leukemia: CD22 is an adhesion molecule almost exclusively restricted to the B cell lineage and expressed in most B-ALL cases (70–73), making CD22 an ideal candidate as a second antigenic specificity added to CD19 for the dual approach to CAR T therapy in ALL (74).